HCR Monthly Blog

The US Biotech Drug Pricing Challenge

April 21st, 2014 Tom Norton

In the midst of the hue and cry last week over the public release of individual Medicare payments to physicians, I was surprised to read that one of Medicare’s most costly medical services is — ophthalmology. According to the New York Times: “One of the most heavily reimbursed procedures — costing a total of $1 read more

 

The Sovaldi Case: Is American Biotech History About to Repeat Itself?

April 2nd, 2014 Tom Norton

Twenty years ago in May, US Senator Joe Lieberman carefully questioned biotech CEO Harry Penner of then Neurogen Corporation about why his company’s stock had taken a dive [transcript p. 94]: Sen. Lieberman: Do you have any doubt that the actions that were at least included in the original Administration (Clinton Health Care) proposal, such read more

 

‘Close Call’ for American Rx Marketers on Medicare Part D

March 12th, 2014 Tom Norton

As the U.S. heads towards a public market place in which Medicare, Medicaid, CHIPs, VA, and now Obamacare will shortly comprise almost 70% of the American healthcare market (http://goo.gl/SLRuC), American Rx marketers recently endured a “close call” with the U.S. Department of Health and Human Services over the arbitrary deletion of dozens of key drugs read more

 

Bringing New Rx Drugs to Market in 2014

February 19th, 2014 Tom Norton

I did something today that I haven’t done in years: I checked out the US pharmaceutical R&D spend versus the rest of the world. Having known since the 80’s that the US owned this space, a quick look at the latest R&D figures confirmed my decades old understanding of the industry’s worldwide position. Today, based read more